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Increasingly, vaccine efficacy studies are being recommended in low-and-middle-income
countries (LMIC), yet often facilities are unavailable to take and store infant blood samples
correctly. Dried blood spots (DBS), are useful for collecting blood from infants for diagnostic
purposes, especially in low-income settings, as the amount of blood required is miniscule
and no refrigeration is required. Little is known about their utility for antibody studies in chil-
dren. This systematic review aims to investigate the correlation of antibody concentrations
against infectious diseases in DBS in comparison to serum or plasma samples that might
inform their use in vaccine clinical trials.
Methods and findings
We searched MEDLINE, Embase and the Cochrane library for relevant studies between
January 1990 to October 2020 with no language restriction, using PRISMA guidelines,
investigating the correlation between antibody concentrations in DBS and serum or plasma
samples, and the effect of storage temperature on DBS diagnostic performance.
We included 40 studies in this systematic review. The antibody concentration in DBS
and serum/plasma samples reported a good pooled correlation, (r2 = 0.86 (ranged 0.43 to
1.00)). Ten studies described a decline of antibody after 28 days at room temperature com-
pared to optimal storage at -20˚C, where antibodies were stable for up to 200 days. There
were only five studies of anti-bacterial antibodies.
Conclusions
There is a good correlation between antibody concentrations in DBS and serum/plasma
samples, supporting the wider use of DBS in vaccine and sero-epidemiological studies, but
there is limited data on anti-bacterial antibodies. The correct storage of DBS is critical and
may be a consideration for longer term storage.
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Introduction
Infectious diseases are a major global cause of morbidity and mortality affecting all age groups,
especially young infants. Many of these diseases could be prevented through vaccination.
However, vaccine clinical trials require blood draws from infants, which are often difficult
because of both the volume required and the need for correct handling and storage of the
sample [1]. This is especially true in low-income countries because of issues with cold chain
maintenance and logistics of transportation from remote locations to a centralised research
laboratory for processing. Detection and quantification of antibodies in the serum/plasma,
offer a rapid and accurate assessment of vaccine responses. To use serum/plasma samples for
serological tests, trained healthcare professionals are required to draw blood [2,3]. As well as a
trained professional, there is a need for specific equipment such as vacutainers to collect whole
blood and a centrifuge to separate serum/plasma from whole blood. Aside from specialised
equipment, freezers are required to store the samples optimally prior to analysis. Due to the
expensive nature of handling (i.e. storage, electricity) of blood samples, vaccine clinical trials
are often problematic in a resource-limited setting [1]. Dried blood spots (DBS) would be a
possible alternative, as they require a less complex procedure to collect than whole blood, espe-
cially from young infants [3,4].
The use of DBS as a diagnostic tool dates back to the 19th century, pioneered by Robert
Guthrie for neonatal metabolic disorder screening [5]. In addition to screening for metabolic
disorders, DBS cards have been utilised for human immunodeficiency virus (HIV) screening,
laboratory quality control, drug testing and detection of pathogens in diverse sample types,
including blood and dried plasma spots [6,7]. Numerous studies have also demonstrated
that antibodies can be detected on DBS, such as in the prospective cohort study of congenital
cytomegalovirus [8] and HIV infection [9]. DBS samples are cost-effective as easily portable
equipment (i.e. lancet device and Whatmann 909 paper) can be used and does not require any
specialist training.
Regardless of the broad use of DBS in a wide range of immunological bioanalyses, sensitiv-
ity and specificity remains uncertain regarding antibody quantification. There are no approved
regulations or manufacturers’ guideline on assay protocols for quantifying antibody concen-
tration in DBS. There are also differences in DBS in terms of the cards themselves including
the size and thickness of the spots and the material used to manufacture the cards. Further,
there are no guidelines on how analysis should be conducted, including optimal elution
methods.
This systematic review aims to assess the evidence for the use of DBS to accurately measure
antibody concentrations from natural exposure and vaccination. Further, we review long-term
DBS storage conditions in preparation for future sero-epidemiological or vaccine studies.
Methodology
The protocol used for this review is registered with PROSPERO [CRD42019127840].
Search strategy
PRISMA was used as a guideline to conduct this systematic review [10]. We searched the elec-
tronic databases Embase, Medline and Cochrane library for studies published between January
1st, 1990 and October 15th 2020, comparing antibody levels in serum/plasma and DBS
obtained from individuals below the age of 80 years. We additionally searched for articles
describing stability of DBS at different storage temperatures over time. No language restriction
was applied. The search strategy used a combination of MeSH and free terms for ‘dried blood
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spot’ OR ‘Guthrie card’ AND ‘antibody’. The database was last searched on the 15th October
2020.
The PRISMA checklist and the full search string are available in the S2 Method.
Eligibility criteria
The studies that were considered eligible for inclusion were original research articles, con-
cerning infectious diseases in humans, comparing antibody titres/concentrations in serum/
plasma to DBS or describing stability of antibodies in DBS from longitudinal studies of
storage at different temperatures. We included studies from all countries. Opinion pieces,
reviews, comments, letters and conference abstracts were excluded. Studies that used ani-
mals to compare antibody levels in serum/plasma and DBS were also excluded. Studies that
had insufficient data (absence of two or more of the following: number of participants, age,
sensitivity, specificity, correlation of antibody levels in matched DBS-serum/plasma sam-
ples) were also excluded. Additionally, we included all studies that investigated the stability
of antibodies in DBS samples.
Study selection
Two independent reviewers (FA and EA) screened the titles and abstracts of the identified
studies. After the initial screening, the reviewers obtained full texts of reports and they inde-
pendently reviewed each article to determine whether it would be included in the final review.
Disagreement on studies were resolved in discussion with a third reviewer (KLD).
Data extraction
The reviewers (FA and EA) independently extracted the data from the included studies using
PICO (patient, intervention, comparison and outcome) [11]. The following information was
extracted from the selected studies: author, publication year, country, journal, infectious dis-
ease, aim of research, study design, duration of study, number of participants, mean age, sensi-
tivity, specificity, method of sample collection, method of sample storage, laboratory tests used
for confirmation, elution method and outcome. The country income of the included studies
was classified by using their respective gross domestic product (GDP) using the World Bank
[12]. All studies were either classified as a low-middle income country (LMIC) (which con-
sisted of low-income, lower middle-income and upper middle-income countries) or as a high-
income country (HIC).
Data synthesis and analysis
Due to the high heterogeneity of study design, participants and outcomes, we were only able to
conduct a narrative synthesis of included studies, summarising the findings with respect to
each infectious disease. We calculated the pooled estimates of specificity, sensitivity and corre-
lation coefficient using the accuracy data (true positive, true negative, false positive and false
negative).
Risk of bias
The risk of bias was assessed by FA using the Cochrane Risk of Bias for non-randomised stud-
ies (ROBINS-I) tool [13]. This included information on bias due to confounding, bias in selec-
tion of participants into the study, bias in classification of interventions, bias due to deviations
from intended interventions, bias due to missing data, bias in measurement of outcomes and
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bias in selection of the reported results. Due to the nature of the interventions considered in
this review, the study’s participants could not be blinded.
Results
We identified 1,508 studies from the electronic databases published between 1st January 1990
to 15th October 2020. Using our search term, we sourced 789 papers from Medline, 667 from
Embase and 52 from Cochrane. After the removal of duplicates, 837 studies were identified for
abstract screening. A total of eighty-eight full text studies were assessed for eligibility, forty
studies met the criteria for inclusion (Fig 1). An additional five papers investigating only anti-
body stability were also included.
Study characteristics
The characteristics of the included studies are summarised in Table 1 and the antibody assess-
ment is summarised in Table 2. Overall, DBS and serum samples from 16,255 individuals were
included: 13,742 (84.5%) adults, 560 (3.4%) 5- to 17-year old’s and 2,082 (12.8%) less than five
years old. Two studies reported antibodies against hepatitis A [14,15], nine hepatitis B [16–
18,26–28,46,48,51], ten hepatitis C [19–22,26–28,37,46,48], eight HIV [23–28,46,50], three
human papillomavirus (HPV) [29,30,37], three measles [31,32,42], three rubella [33,34,42],
two syphilis [40,46], two H. pylori [35,47] and two malaria [38,49]. Twelve papers reported on
Chagas disease [35], Epstein-Barr virus [36], HPV, H. pylori, hepatitis C and polyomavirus
[37], Strongyloidiasis [39], pertussis [41], hepatitis E [56], Vibrio cholera [2], measles, mumps
and rubella [42], tuberculosis and cytomegalovirus [43], toxoplasmosis [44], trypanosoma
[45], Covid-19 [52], respectively.
Twelve studies were conducted in Europe [14,18,21,27,29,30,35,41–43,50,52], four in North
America [19,20,32,36], eleven in South America [15–17,22,24,34,38,39,48,49,51], seven in
Africa [23,25,26,31,40,44,45] and five in Asia [28,33,37,46,47].
The risk of confounding was high in all included studies as the risks for measure of out-
comes, missing data and deviation from intended interventions were unclear (S1 Table).
Twenty-two of the studies had a moderate risk of bias for reporting [15,17–19,22,24,27–
32,35,37,39,40,44,46–48,51,52], whereas, seventeen of the studies had a high risk of bias for
reporting [14,16,20,21,23,25,26,33,34,36,38,41–43,45,49,50]. All studies had an overall high
risk of bias (S1 Table). Blinding the laboratory personnel to the results of tests were not
reported in any of included studies. Thirteen studies reported the stability of DBS, 35 out of
the 39 studies reported the elution method and 33 out of the 39 studies reported the diagnostic
performance.
Elution method
Thirty-two (89%) reported the methodology used to elute the DBS samples [14,15,17–32,35–
37,39–42,44–52]. The shortest incubation period of the DBS in elution buffer (50 μl 0.05%
PBS/Tween-20) was 30 minutes [42] and the longest incubation period of the DBS in elution
buffer (700 μl and 300 μl PBS/0.05% BSA) was 18–24 hours [17]) (Table 2). Nine studies used
only phosphate buffered saline (DBS size ranging from 1.1-mm to 12-mm diameter, quantity
of buffer ranging from 100 μl to 450 μl) to elute the DBS [17–19,25,26,32,35,37,44]. Eight stud-
ies used phosphate buffered saline with Tween (DBS size ranging from 3-mm to 12-mm diam-
eter, quantity of buffer ranging from 50 μl to 800 μl) to elute the DBS [17,20,29,30,39,40,42,52].
Two studies compared the effect of different types of elution buffers [17,46]. Villar et al’s study
found that DBS samples eluted in PBS/0.5% BSA had the lowest levels of non-specific reactivity
in comparison to PBS alone, PBS/Tween 20 0.05%, PBS/Tween 20 0.05%/0.005% Sodium
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Fig 1. Prisma flowchart. Flowchart of studies included in the systematic review on detecting antibodies from DBS compared to venous
blood samples (plasma/serum).
https://doi.org/10.1371/journal.pone.0248218.g001
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Table 1. Characteristics of the included studies.
AUTHOR, YEAR COUNTRY GDP STUDY PERIOD STUDY
DESIGN
SAMPLE SIZE AGE DISEASE CONCLUSION
GIL A, 1997 [14] Spain HIC Nr Cross-
sectional
298 15.3 ± 1.2 years HAV Anti-HAV antibodies
are stable on DBS and





Brazil LMIC March 2007 Cross-
sectional





can be used to detect
anti-HAV antibodies in





Brazil LMIC Nr Cross-
sectional
155 Adults (18 and
above)
HBV Amongst HIV positive
and negative subjects,





Brazil LMIC 183 days Cross-
sectional
522 Adults (18 and
above)
HBV Good correlation of
HBV markers in serum
and DBS









France HIC Nr Cohort 230 Adults (18 and
above)



















USA HIC Samples collected




33 Adults (18 and
above)
HCV The sensitivity of anti-






France HIC Nr Case-control 200 Adults (18 and
above)
HCV DBS is reliable as serum
specimens and it can be













volume due to low
amount of antibody
levels as compared to
sera samples
(Continued)
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Table 1. (Continued)
AUTHOR, YEAR COUNTRY GDP STUDY PERIOD STUDY
DESIGN
SAMPLE SIZE AGE DISEASE CONCLUSION
SARGE-NIJE R,
2006 [23]
Gambia LMIC Nr Cross-
sectional
200 Adults (18 and
above)










Brazil LMIC 2005–2006 Cross-
sectional
457 Ranged from 2
months to 78
years







Sierra Leone LMIC April 1994 Cross-
sectional
359 Adults (18 and
above)

















of DBS assay obtained
in this study for HCV
and HBV
The ODs of DBS from
HIV, HCV or HBV
positive subjects did not
overlap with ODs of
DBS samples from
negative individuals
ROSS S, 2013 [27] Germany HIC Nr Cross-
sectional




There is a good
correlation of antibody
levels across the three
diseases in matched
serum and DBS.








DBS is as reliable as
serum, although
different cut-off points
need to be used to








HPV A strong correlation
between anti-HPV16L1
IgG and IgA was
observed in serum and
DBS.









levels of DBS are slightly
lower than serum; DBS
is an appropriate
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Table 1. (Continued)
AUTHOR, YEAR COUNTRY GDP STUDY PERIOD STUDY
DESIGN
SAMPLE SIZE AGE DISEASE CONCLUSION
UZICANIN A, 2011
[31]












Measles Although the non-
measles group had a low
concordance group; the
overall findings indicate
that DBS are a feasible



















Measles It is feasible to conduct
sero-surveys using DBS
samples in low-resource
settings, as the antibody
levels are highly
consistent in matched
serum and DBS samples
PUNNARUGSA V,
1991 [33]
Thailand LMIC Nr Cross-
sectional
1000 Adults (18 and
above)












Rubella There was a good
correlation between
serum and DBS; which
suggests that DBS is an
acceptable to be used as








147 Adults (18 and
above)
Chagas With a cut-off point of
�0.88, there are low
numbers of false-
negative DBS
EICK G, 2017 [36] USA HIC November 2014-
February 2015




This study showed that
there is a high
correlation of Epstein-











There was a good
correlation between






Brazil LMIC September 1996 Retrospective 210 1–64 years
(25.3 years)


















SMIT P, 2013 [40] Tanzania LMIC Nr Cohort 1645 15–84 years
(31.9 years)
Syphilis It is recommended that
Treponema pallidum
particle agglutination
assay is used to quantify
antibody levels in DBS
(Continued)
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Table 1. (Continued)
AUTHOR, YEAR COUNTRY GDP STUDY PERIOD STUDY
DESIGN
SAMPLE SIZE AGE DISEASE CONCLUSION
VAN OMMEN C,
2012 [41]






Pertussis Anti-PT IgG from cord
blood in DBS and













(1) Antibodies are stable
for at least for 2 weeks
at room temperature
(2) The antibody levels
DBS and serum showed
a good agreement as




Finland HIC Nr Cross-
sectional










Egypt LMIC Nr Cross-
sectional
101 10–70 years Toxoplasmosis DBS can be used to test












The high sensitivity and
specificity suggests that




MA J, 2020 [46] China HIC Nr Cross-
sectional













India LMIC January 2018-
May 2018
Observational 88 Adults (18 and
above)
H. pylori No difference in
antibody levels were










HBV and HCV Although the sensitivity
% for anti-HBc, DBS

















antibodies, it is better to




France HIC Nr Cross-
sectional
10 Adults (18 and
above)
HIV This study is further
showing evidence that
DBS samples are also
suitable for detecting
HIV antibodies, as well
as, for use in population
surveillance
(Continued)
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azide and PBS/Tween 20 0.2%/5% BSA. Whereas, Ma et al found that eluting DBS spots in
500 μl of 1%Tween-20/PBS resulted in the highest antibody recovery.
Diagnostic performance
Thirty of the studies used enzyme-linked immunosorbent assays (ELISA) [14–17,19,21–26,29–
32,34,36,38,39,41–47,49–52] with the one study using the Luminex 100 [37] or a combination
of Treponema pallidum particle agglutination assay (TPPA), Treponema pallidum hemagglu-
tination assay (TPHA) and ELISA [40]. Two studies used the architect system [27,35] as a
detection method and two studies used chemiluminescence immunoassay (CIA) either alone
[18] or in combination with ELISA [20]. The method of antibody quantification was unclear
in one study [35] and not reported in another study [28] (Table 2).
Thirty-three of the included studies reported the sensitivity [14–28,30–35,37,40,42,44–52]
and twenty-six reported the specificity [14,15,17–28,30–33,35,40,44–49,51,52] of antibodies on
DBS (Fig 2). The pooled sensitivity for all the infectious diseases ranged from 35.2% to 100%
with a mean of 98.8% and the pooled specificity ranged from 50.4% to 100% with a mean of
95.4%. The highest mean sensitivity and specificity reported were for HIV; 97.5% and 99.6%,
respectively [23–28].
The lowest mean sensitivity reported were for the malaria (P. vivax) study; 50% [49]
whereas the lowest specificity reported were for syphilis; 50.4% (ELISA) [40] (Table 3).
Nineteen studies reported the correlation between antibody concentration in DBS and
serum or plasma samples [13,15–17,20,24,26,28–30,32–37,39]. The pooled correlation of anti-
body concentration in DBS and serum/plasma samples ranged from 0.43 to 1.00 with a mean
of 0.86. The highest correlation of antibody titers in DBS and serum/plasma samples was
observed for Coronavirus, which was 0.97 [52]. The lowest mean correlation of DBS and
serum/plasma were observed for the measles study; 0.33 [31] (Table 3).
Storage of DBS cards
Twenty-one studies reported that their DBS samples were stored at -20˚C [17,19,22–
24,26,27,30,33,34,36,39,41–43,46,48–50,53], three studies stored at -80˚C [37,38,44], five stud-
ies stored at 4˚C [16,31,32,44,51], two studies stored at room temperature [20,35] and in two
studies the DBS’s were stored at -5˚C to -10˚C [40] and -70˚C [21], respectively (Table 2).
Table 1. (Continued)
AUTHOR, YEAR COUNTRY GDP STUDY PERIOD STUDY
DESIGN
SAMPLE SIZE AGE DISEASE CONCLUSION
CRUZ H, 2020 [51] Brazil LMIC 2009–2014 Cross-
sectional
2309 Adults (18 and
above)
HBV HBsAg in DBS samples
had the best sensitivity
percentage in this study.
This study showed that





UK HIC 2020 Cross-
sectional
87 Adults (18 and
above)
Coronavirus The results of this study
illustrate that antibodies
in DBS samples are
highly comparable to
serum samples
Abbreviations: a GDP: Gross domestic product; b HIC: High Income Country; c LMIC: Lower Middle-Income Countries; d HAV: Hepatitis A virus; e HBV: Hepatitis B
virus; f HCV: Hepatitis C virus; g HIV: Human Immunodeficiency virus; h HPV: Human papillomavirus; i anti-HBs: Hepatitis B surface antibody; j Nr: Not reported.
https://doi.org/10.1371/journal.pone.0248218.t001
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Table 2. Immunological assessment of the included studies.




ELUTION METHOD OF DBS SAMPLE
STORAGE
GIL A, 1997 [14] DBS and serum ELISA DBS were eluted for 12 hours at room temperature in 1 ml of





DBS and plasma ELISA 12.5mm-diameter DBS were eluted at 4˚C overnight in 350 μl
PBS/0.2% Tween-20/5% bovine plasma albumin
-20˚C
FLORES L, 2018 [16] DBS and serum ELISA Nr Nr
VILLAR M, 2011 [17] DBS and serum ELISA 6-mm DBS samples were eluted in 700 μl of PBS/0.5% BSA for
HBsAg and anti-HBc antibody quantification. 12.5mm DBS
samples were eluted in 300 μl of PBS/0.5% BSA for HBsAg and
anti-HBc antibody quantification. All DBS samples were




DBS and plasma CIA 12-mm diameter DBS were eluted at room temperature in
continued agitation in 450 μl PBS
DBS: RMT;
Serum: Nr





DBS and plasma CIA and ELISA 12-mm diameter DBS were eluted overnight at 4˚C in 500 μl PBS/
Tween
-20˚C for 5 years
TUAILLON E, 2010
[21]
DBS and serum ELISA 6-mm diameter DBS were eluted on shaker overnight in 200 μl





DBS and serum ELISA 3-mm diameter DBS were eluted for 18–24 hours at 4˚-8˚C in




DBS and serum ELISA 5.5-mm diameter DBS eluted overnight at 4˚C in 100 μl or 200 μl
PBS/Tween-20/0.005% Sodium azide
Nr
CASTRO A, 2008 [24] DBS and serum ELISA 4.7-mm diameter DBS eluted in ELISA kit sample diluent DBS: -20˚C;
Serum: Nr
BOILLOT F, 1997 [25] DBS and serum ELISA DBS in PBS was placed on rotatory shaker for 90 mins, followed
by overnight incubation at 4˚C
-20˚C
KANIA D, 2013 [26] DBS and plasma ELISA 6-mm diameter DBS were eluted overnight in 300 μl (HBsAg and
HCV) or 150 μl (anti-HBc) PBS
Nr
ROSS S, 2013 [27] DBS and serum Architect system DBS were eluted overnight at room temperature on a shaker in 1
ml PBS/0.05% Tween-20/0.08% Sodium azide
Nr




BHATIA R, 2019 [29] DBS and serum ELISA DBS were eluted in 800 μl PBS/0.05% Tween-20 DBS: 4˚C; Serum:
Nr
LOUIE K, 2018 [30] DBS and serum ELISA 9x 2-mm diameter DBS were eluted overnight at 4˚C on a shaker




DBS and serum ELISA 6.35-mm diameter DBS were eluted in 250 μl PBS/Tween-20/5%
non-fat dry milk followed by placing it on a plate shaker for 30
mins. Following on, the samples were incubated for 16 hours at
4˚C
-20˚C





DBS and serum Unclear Unclear DBS: RMT;
Serum: -20˚C
HELFAND F, 2007 [34] DBS and serum ELISA Nr -20˚C
HOLGUIN A, 2013
[35]
DBS and serum Architect Chagas assay 2x 1.1-mm diameter DBS were eluted overnight at room
temperature on a shaker in 300 μl PBS
-80˚C
EICK G, 2017 [36] DBS and plasma ELISA 3.2-mm diameter DBS were eluted overnight at 4˚C on a shaker in




DBS and serum Multiplex serology (Luminex
100 analyser)
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Thirteen studies investigated the stability of antibodies in DBS samples stored at different
temperatures (Table 4). Six studies [2,21,23,35,55] concluded that antibody levels in DBS were
stable at room temperature, ranging from 7 days to 28 days. A slight decline was observed in
antibody concentrations in DBS samples that were stored at 2–8˚C, although five studies
[2,26,46,55,58] demonstrated that DBS samples were stable for up to 210 days at this tempera-
ture (range of storage time: 7 to 210 days). Five studies [26,38,55,57,58] found that antibodies
in DBS samples stored at 37˚C were unstable with antibody concentrations steadily declining
in as few as three days [55]. One study showed that antibodies in DBS samples stored at 37˚C
Table 2. (Continued)




ELUTION METHOD OF DBS SAMPLE
STORAGE





DBS and serum ELISA 8 DBS were eluted overnight at room temperature in PBS/Tween-
20
-20˚C
SMIT P, 2013 [40] DBS and plasma TPPA, ELISA and TPHA 6-mm diameter DBS were eluted overnight at 4˚C in 100 μl PBS/
0.05% Tween-80
-20˚C
VAN OMMEN C, 2012
[41]
DBS and serum ELISA 2x 3.18-mm diameter DBS were vortexed at room temperature for




DBS and serum ELISA DBS were eluted at room temperature for 30 mins in agitation in
50 μl 0.05% PBS/Tween-20
DBS: 4˚C; Serum:
-20˚C
AABYE M, 2012 [43] DBS and plasma ELISA Unclear -80˚C
HEGAZY M, 2020 [44] DBS and serum ELISA DBS were eluted in 0.2mL PBS at room temperature overnight on
an automatic shaker. Samples were then centrifuged at 1000xg for
10 minutes
-20˚C
GEERTS M, 2020 [45] DBS and plasma ELISA 6-mm DBS spots were eluted overnight in 400 μl g-iELISA sample
diluent
Nr
MA J, 2020 [46] DBS and plasma ELISA DBS samples were eluted for comparison for all three antibodies
in 1%Tween-20/PBS, 1%TritonX100/PBS, 1%Tween-20 and 1%
TritonX100. Furthermore, the elution effect of Tween-20/PBS
buffer was compared at 1% and at 3%
DBS: -20˚C;
Plasma: -20˚C
KUMAR A, 2019 [47] DBS and plasma ELISA 6-mm DBS spot was eluted in 500 μl of diluent buffer (part of the
ELISA kit) for 2–3 hours at room temperature on a plate shaker
DBS: -20˚C;
Plasma: -80˚C
VILLAR L, 2020 [48] DBS and serum PCR For anti-HCV, a 3-mm spot was placed into a microtube
containing 300 μl of PBS/0.5%BSA at 4–8˚C for 18–24 hours. A
6-mm spot was eluted in 700 μl of PBS/0.5%BSA at 4–8˚C for 18–








STEFIC K, 2019 [50] DBS and plasma ELISA 6-mm spot was placed in 150 μl 0.01M-PBS/10%BSA/0.05%
Tween-20 and it was incubated overnight at 4˚C
Nr
CRUZ H, 2020 [51] DBS and serum ELISA To detect HBsAg and total anti-HBc, a 6-mm DBS spot was eluted
in 700 μl PBS/0.05%BSA. For anti-HBc detection, a 12.5 mm spot
was eluted in 300 μl of PBS/0.05%BSA.
-20˚C
MORLEY G, 2020 [52] DBS and serum ELISA One DBS spot was eluted in 250 μl of 0.05% PBS/Tween-20. The
tubes were briefly vortexed before it was incubated overnight at
toon temperature. On the following day the tubes were
centrifuged for 10 minutes at 10,600 xg at room temperature.
Nr
Abbreviations: a HAV: Hepatitis A virus; b HCV: Hepatitis C virus; c HIV: Human Immunodeficiency virus; d HPV: Human papillomavirus; e HBsAg: Hepatitis B
surface antigen; f anti-HBc: Hepatitis B core antibody; g anti-HBs: Hepatitis B surface antibody; h BSA: Bovine serum albumin; i CIA: Chemiluminescence immunoassay;
i PBS: Phosphate buffered saline; j PCR: Polymerase chain reaction; kTPPA: Treponema pallidum particle agglutination assay; l TPHA: Treponema pallidum
hemagglutination assay; m Nr: Not reported; n RMT: Room temperature.
https://doi.org/10.1371/journal.pone.0248218.t002
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were stable until the 7th day [2]. Nine studies [2,19,24,26,38,46,55–57] demonstrated minimal
variations in antibody concentrations compared to baseline cards stored at -20˚C, over 21 to
200 days.
Storage of DBS cards
Twenty-one studies reported that their DBS samples were stored at -20˚C [15,17,20–
22,24,25,28,31,32,34,37,39–41,44,46–48,51], three studies stored at -80˚C [35,36,42], five stud-
ies stored at 4˚C [14,29,30,42,49], two studies stored at room temperature [18 = 33] and in two
studies the DBS’s were stored at -5˚C to -10˚C [38] and -70˚C [19], respectively (Table 4).
Thirteen studies investigated the stability of antibodies in DBS samples stored at different
temperatures (Table 4). Six studies [2,19,21,33,54] concluded that antibody levels in DBS were
stable at room temperature, ranging from 7 days to 28 days. A slight decline was observed in
antibody concentrations in DBS samples that were stored at 2–8˚C, although five studies
[2,24,44,53,56] demonstrated that DBS samples were stable for up to 210 days at this tempera-
ture (range of storage time: 7 to 210 days). Five studies [24,36,53,55,56] found that antibodies
in DBS samples stored at 37˚C were unstable with antibody concentrations steadily declining
in as few as three days [53]. One study showed that antibodies in DBS samples stored at 37˚C
were stable until the 7th day [2]. Nine studies [2,17,22,24,36,44,53–55] demonstrated minimal
variations in antibody concentrations compared to baseline cards stored at -20˚C, over 21 to
200 days.
Discussion
To our knowledge, this is the first comprehensive systematic review to summarise the utility of
DBS considering the key aspects of storage, assay methods and card handling which are all
important considerations for vaccine trials and serological studies. Overall, the diagnostic
accuracy and precision was high when comparing serum/plasma to DBS, indicating that DBS
are a useful alternative to serum.
In a review of anti-HCV antibodies eluted from DBS, Vazques-Moron et al reported a sen-
sitivity of>96% and a specificity of>99% for anti-HCV antibodies in DBS samples [57].
Their reported figures are similar to the pooled diagnostic performances we have shown. How-
ever, our pooled results indicate that there may be differences in both sensitivity and specificity
depending on the pathogen type. A study of SARS-COV-2 antibodies demonstrated that sensi-
tivity of matched plasma and DBS was 98.9% [52]. This is potentially useful knowledge during
Fig 2. Scatterplot of diagnostic performances (sensitivity and specificity) based on pathogen type.
https://doi.org/10.1371/journal.pone.0248218.g002
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Table 3. Sensitivity, specificity and r2 of the included studies.
AUTHOR, YEAR SENSITIVITY SPECIFICITY CORRELATION (R2) OF ANTIBODY LEVELS IN
DBS AND SERUM/PLASMA
GIL A, 1997 [14] 91.30% 99.30% Nr
MELGACO J, 2011 [15] 100% 100% 0.6262
FLORES L, 2018 [16] Anti-HBs in HIV- individuals: 79.8%
Anti-HBs in HIV+ individuals: 76.8%
Nr Nr
VILLAR M, 2011 [17] HBsAg: 95.45%; Anti-HBc: 89.19%;
Anti-HBs: 83.05%
HBsAg: 70.79%; Anti-HBc: 97.53%; Anti-
HBs: 81.33%
0.832
MOHAMED S, 2013 [18] 98% 100% 0.98
DOKUBO K, 2014 [19] Anti-HCV: 70% Anti-HCV: 100% 0.69
TEJADA-STROP A, 2015
[20]
CIA- 100%; ELISA- 97% CIA- 100%; ELISA- 100% Nr
TUAILLON E, 2010 [21] 99% 98% Nr
BRANDAO C, 2013 [22] 95.00% 100% 0.971
SARGE-NIJE R, 2006
[23]
Ranged from 95% to 100% [depending
on which assay was used]
Ranged from 97.5% to 100% [depending
on which assay was used]
Nr
CASTRO A, 2008 [24] 100% 99.60% Nr
BOILLOT F, 1997 [25] 87.50% 100% Nr
KANIA D, 2013 [26] HBsAg: 96%; Anti-HBc: 99.3%;
HIV: 100%; HCV: 100%
HBsAg: 100%; Anti-HBc: 98.7%;
HIV: 100%; HCV: 100%
HBsAg: 0.98; Anti-HBc: 0.98;
HIV: 1.00; HCV: 1.00
ROSS S, 2013 [27] HBsAg: 98.6%; Anti-HBc: 97.1%;
Anti-HBs: 97.5%; Anti-HCV: 97.8%;
Anti-HIV ½: 100%
HBsAg: 100%; Anti-HBc: 100%;
Anti-HBs: 100%; Anti-HCV: 100%;
Anti-HIV ½: 100%
Nr
LEE C, 2011 [28] HIV: 100%; HBsAg: 96.5%;
Anti-HBs: 74.2%; Anti-HCV: 100%
HIV: 100%; HBsAg: 97.8%;
Anti-HBs: 86.9%; Anti-HCV: 100%
HIV Ag/Ab: 0.824; HBsAg: 0.432;
Anti-HBs: 0.721; Anti-HCV: 0.631
BHATIA R, 2019 [29] Nr Nr Nr
LOUIE K, 2018 [30] 94% 98% 0.961
UZICANIN A, 2011 [31] Measles (week 1 after rash): 98.7%
Non-measles: 50%
Measles (week 1 after rash): 88.9%
Non-measles: 100%
Measles (week 1 after rash): 0.71
Non-measles: 0.33








HOLGUIN A, 2013 [35] 98.80% 71.60% 0.803
EICK G, 2017 [36] Nr Nr 0.93
WATERBOER T, 2012
[37]
HPV: 94.5%; H. pylori: 96.6%;
HCV: 98%; Polyomavirus: 98%
Nr H. pylori, HCV, JCV: 0.88;
HPV: 0.79
DUARTE E, 2002 [38] Nr Nr 0.95
FORMENTI F, 2016 [39] Nr Nr 0.921












Measles: 98.6%; Mumps: 96%;
Rubella: 99.1%
Nr Nr
AABYE M, 2012 [43] Nr Nr Nr
HEGAZY M, 2020 [44] 100% 100% Nr
GEERTS M, 2020 [45] 92.6% 100% Nr
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the pandemic as DBS could be used as an alternative to blood samples for national surveillance.
DBS sampling would be more convenient for sampling as it does not require attendance at
clinic to collect samples and samples can be easily sent back by post.
There are no guidelines on how DBS samples should be stored for short- and long-peri-
ods of time and this is evident from the variable storage described in the studies we reviewed.
We have demonstrated that storage at room temperature (22–28˚C) is acceptable for up to
28 days; making the transportation of DBS samples straightforward, especially in environ-
ments lacking cold chain. However, we also report that longer term storage should be at
refrigerated or frozen temperatures after 28 days at room temperature, as antibodies
degraded significantly thereafter. Overall, our results indicate that -20˚C is the optimum
temperature to store DBS samples for prolonged periods and it may be necessary for this to
be factored into trials where samples may be stored for several years prior to use. This is con-
sistent with the national laboratory guidelines in Denmark [58], Scotland [59], US [60] and
Germany [61], which all recommend long term freezer storage. Williams et al [62] re-quan-
tified anti-HIV antibodies in four high positive controls that were initially spotted 23 years
prior to the analysis. The antibody concentrations obtained were the same as those measured
23 years prior when stored at -20˚C. Yel et al’s [44] study found that IgA antibodies were sta-
ble for up to 14 days at room temperature and at 4–8˚C, however, IgA antibodies were stable
for up to 10 days when stored at -20˚C. Going forward, it may be useful to determine the sta-
bility of the different antibody isotypes, as certain antibodies may be more stable than others
on DBS.
Whilst this review provides support for the use of DBS for the investigation of immunity to
several pathogens, we found only four studies which investigated the antibody concentration
against bacterial infections. It is vital that more research is undertaken to understand the sta-
bility of antibodies against bacterial infections in DBS samples and how antibody concentra-
tions compare to serum or plasma samples. This is of particular importance if DBS are to be
used in vaccine trials against bacterial pathogens, which are required to reduce the impact of
the continued spread of antibiotic resistance.
There is of considerable urgency as many bacterial infections are becoming increasingly
antibiotic resistant and DBS could be used as part of studies to measure vaccine or natural
immunity to bacterial infections [63].
Table 3. (Continued)
AUTHOR, YEAR SENSITIVITY SPECIFICITY CORRELATION (R2) OF ANTIBODY LEVELS IN
DBS AND SERUM/PLASMA
KUMAR A, [47] Anti-H. pylori: 87.5% Anti-H. pylori: 95% Nr
VILLAR L, 2020 [48] HBsAg: 100%; Anti-HBc: 66.6%;
Anti-HCV: 75%






STEFIC K, 2019 [50] 98.9% Nr Nr







MORLEY G, 2020 [52] 98.11% 100% 0.975
Abbreviations: a anti-HBc: Hepatitis B core antibody; b anti-HBs: Hepatitis B surface antibody; c CIA: Chemiluminescence immunoassay; d ELISA: Enzyme-linked
immunosorbent assay; e HAV: Hepatitis A virus; f HCV: Hepatitis C virus; g HIV: Human Immunodeficiency virus; h HPV: Human papillomavirus; i HBsAg: Hepatitis
B surface antigen j Nr: Not reported; k TPPA: Treponema pallidum particle agglutination assay; l TPHA: Treponema pallidum hemagglutination assay.
https://doi.org/10.1371/journal.pone.0248218.t003
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Table 4. Optimal temperature for dried blood spot storage.
AUTHOR, YEAR TEMPERATURE DAYS OPTIMUM TEMPERATURE TO STORE DBS FOR MAXIMUM ANTIBODY
RECOVERY
IYER A, 2018 [2] 37˚C (humid), 37˚C (non-humid),
Rmt (~22˚C), 4˚C, -20˚C
7 The vibriocidal antibodies on DBS samples were stable across all temperatures for
one week.
VILLAR M, 2011 [17] Rmt (22˚C to 25˚C bag), Rmt (22˚C
to 25˚C), 4˚C to 8˚C, -20˚C
183 For the first 63 days, samples (non-reactive DBS samples to anti-HBc markers)
stored in all the temperatures (4˚C, -20˚C and room temperature) were stable.
However, on day 183, samples stored at -20˚C had the lowest variation of optical
density values.
Reactive DBS samples (HBsAg marker) that were stored at -20˚C were the only
ones which did not result in false-positive. The DBS samples (HBsAg marker)
stored at Rmt became ELISA negative on the 63rd day. DBS samples (anti-HBs)
stored at Rmt resulted in one false-positive result on the 183rd day. Nevertheless,
the DBS samples (anti-HBs) stored at -20˚C had the lowest OD variation.
MOHAMED S, 2013
[19]
Rmt 14 DBS samples (HBsAg and anti-HBs markers) stored at room temperature were
stable for up to 14 days.
TUAILLON E, 2010
[21]
Rmt 12 DBS samples (anti-HCV marker) stored at room temperature were stable for as
long as 12 days.
BRANDAO C, 2013
[22]
Rmt (22˚C to 26˚C), 2˚C to 8˚C,
-20˚C
117 DBS samples (anti-HCV marker) stored at Rmt observed a significant decline in
mean optical density on the 117th day in comparison to the baseline. The lowest




37˚C, Rmt (mean ~22.1˚C), 4˚C,
-20˚C, -70˚C
42 DBS samples (anti-HIV1 marker) stored at 37˚C degraded after the 4th week. The
samples stored at Rmt were stable on the 1st week, however, on the sixth week one
samples which was HIV-positive (with a low optical density) became HIV-




Rmt 28 Antibodies in DBS samples stored at room temperature were stable for as long as
28 days.
EICK G, 2017 [36] 37˚C, Rmt, -20˚C 21 DBS stored (EBV markers) at 37˚C, room temperature and -20˚C were stable for
21 days. Antibodies in DBS samples stored at 37˚C decreased over time. Recovery
of antibodies in DBS samples stored at -20˚C had no clear change; indicating that
-20˚C is the optimum storage temperature for DBS.
HEGAZY M, 2020
[44]
4˚C, -20˚C 4˚C: 1 month
-20˚C: 3 months
Antibodies in DBS samples stored at 4˚C were stable for one month and in
samples that were stored at -20˚C for three months.
YEL L, 2015 [53] 36˚C to 38˚C, Rmt, 2˚C to 8˚C, -20˚C
to -40˚C
14 IgG and IgM antibodies in DBS samples were stable at Rmt, 2˚C to 8˚C and -20˚C
to -40˚C until the 14th day. However, IgG and IgM antibodies in DBS samples
stored at 36˚C to 38˚C resulted in a decrease of antibody concentration after the
4th day.
On the other hand, IgA antibodies in DBS samples stored at Rmt and 2˚C to 8˚C
were stable until the 14th day. The DBS samples (IgA) stored at -20˚C to -40˚C
were only stable until the 10th day, whereas the samples which were stored at 36˚C
to 38˚C were only stable until the 3rd day.
MARQUES B, 2012
[54]
Rmt (20˚C to 26˚C), 2˚C to 8˚C,
-20˚C
117 DBS samples (anti-HCV marker) stored at 2˚C to 8˚C and at -20˚C were stable
until the 117th day. However, the samples (anti-HCV marker) that were stored at
Rmt were stable until the 60th day, followed by a reduction in antibody
concentration on the 117th day.
MCALLISTER G,
2015 [55]
37˚C, Rmt (22˚C to 28˚C), 4˚C,
-20˚C, -70˚C
200 There was a loss of antibody concentration in DBS samples (HBsAg and anti-HBc
markers) stored at 37˚C, Rmt and 4˚C by the 14th day. The samples that were
stored at 37˚C resulted in HBsAg negative for all three patients on the 200th day.
However, the samples (HBsAg and anti-HBc markers) that were stored at -20˚C
and at -70˚C were stable until the 200th day—as there was minimal variation. DBS
samples (anti-HCV marker) were stable at all the temperatures except at 37˚C until
the 200th day. Samples which were stored at 37˚C, resulted in a decline of reactivity
by 89% on the 200th day.
(Continued)
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There are several limitations to this systematic review. Firstly, the quality of the studies
included in this review were generally low (S1 Table), which precluded a meta-analysis of the
data. The filter papers, blood volume collected, size of dried blood spots, elution process and the
assays used for antibody quantification also differed amongst the studies, compounding the lim-
ited translation of results. Furthermore, the variability of the study designs may have also con-
tributed to the heterogeneity which has restricted direct comparisons and prevented any meta-
analysis of data, even of the same pathogen. Secondly, differences in specificity, sensitivity and
correlation were noted for different pathogens, suggesting that antibodies against some patho-
gens in DBS may be less stable than others. Thirdly, the studies did not investigate the effect of
humidity on DBS, which is often an issue in sub-Saharan Africa and Asia. Finally, we acknowl-
edge that heterogeneity exists when different cut-off levels are applied between the studies.
Further data are needed to demonstrate the stability of DBS for different pathogens, espe-
cially bacteria, under different field transport and storage conditions likely to be encountered
in low resource settings, including the effect of high ambient temperature or humidity levels.
Consideration of the use of DBS sampling in clinical vaccine or sero-epidemiological stud-
ies will depend on both healthcare setting and available infrastructure. The current lack of
guidelines for the adaptation of assays from serum to DBS and on the optimal pre-analytical
treatment of specimens makes quality control challenging. With optimal storage, DBS can be a
useful adjunct to serological analysis due to their relative simplicity to take and requirements
for a less rigorous cold chain, saving time and reducing costs.
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Table 4. (Continued)
AUTHOR, YEAR TEMPERATURE DAYS OPTIMUM TEMPERATURE TO STORE DBS FOR MAXIMUM ANTIBODY
RECOVERY
SINGH, P [56] 37˚C, 2˚C to 8˚C 210 The DBS samples (positive for anti-HEV IgM) that were stored at 37˚C were
significantly degraded, as 71.43% of the samples became negative on the 55th day,
therefore samples were not further analysed. The samples that were stored at 2˚C
to 8˚C were stable when tested on the 65th day as all samples were still anti-HEV
IgM positive. However, on the 100th and 130th day, 9.52% and 19.04% of the
samples became anti-HEV IgM negative. Aside from this, no IgM fluctuation was
observed until the 210th day.
Abbreviations: a anti-HBc: Hepatitis B core antibody; b anti-HBs: Hepatitis B surface antibody; c DBS: Dried blood spot; d EBV: Epstein-barr virus; e HBsAg: Hepatitis B
surface antigen; f HCV: Hepatitis C virus; g HIV: Human immunodeficiency virus; h IgA: Immunoglobulin A; i IgG: Immunoglobulin G; j IgM: Immunoglobulin M; k
OD: Optical density; l RMT: Room temperature.
https://doi.org/10.1371/journal.pone.0248218.t004
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